

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

RECKITT BENCKISER PHARMACEUTICALS  
INC., RB PHARMACEUTICALS LIMITED,  
and MONOSOL RX, LLC,

Plaintiffs,

v.

TEVA PHARMACEUTICALS USA, INC.,

Defendant.

Civil Action No. 14-1451-RGA

RECKITT BENCKISER PHARMACEUTICALS  
INC., and MONOSOL RX, LLC,

Plaintiffs,

v.

PAR PHARMACEUTICAL, INC. and  
INTELGENX TECHNOLOGIES CORP.,

Defendants.

Civil Action No. 14-1573-RGA

RECKITT BENCKISER PHARMACEUTICALS  
INC., and MONOSOL RX, LLC,

Plaintiffs,

v.

WATSON LABORATORIES, INC. and  
ACTAVIS LABORATORIES UT INC.,

Defendants.

Civil Action No. 14-1574-RGA

MEMORANDUM OPINION

Mary W. Bourke, Esq., Dana K. Severance, Esq., Daniel M. Attaway, Esq., WOMBLE CARLYLE SANDRIDGE & RICE, LLP, Wilmington, DE; Daniel A. Ladow, Esq. (argued), James M.

Bollinger, Esq., Timothy P. Heaton, Esq., J. Magnus Essunger, Esq., Bennet J. Moskowitz, Esq., TROUTMAN SANDERS LLP, New York, NY; Puja Patel Lea, Esq., TROUTMAN SANDERS LLP, Atlanta, GA; Robert E. Browne, Jr., Esq., TROUTMAN SANDERS LLP, Chicago, IL; Charanjit Brahma, TROUTMAN SANDERS LLP, San Francisco, CA.

Attorneys for Plaintiffs.

Jeffrey B. Elikan, Esq., Jeffrey H. Lerner, Esq., Erica N. Andersen, Esq., COVINGTON & BURLING LLP, Washington, DC; Curt G. Calia, Esq., COVINGTON & BURLING LLP, Redwood Shores, CA.

Attorneys for Plaintiff Reckitt Benckiser Pharmaceuticals, Inc. & RB Pharmaceuticals Limited.

James F. Hibey, Esq., Timothy C. Bickham, Esq., Rachel M. Hofstatter, Esq., STEPTOE & JOHNSON LLP, Washington, DC; David L. Hecht, Esq., STEPTOE & JOHNSON LLP, New York, NY.

Attorneys for Plaintiff MonoSol Rx, LLC.

Megan C. Haney, Esq., John C. Phillips, Jr., Esq., David A. Bilson, Esq., PHILLIPS, GOLDMAN & SPENCE, P.A., Wilmington, DE; Michael K. Nutter, Esq., WINSTON & STRAWN, LLP, Chicago, IL; David P. Dalke, Esq., Ashlea Raymond Pflug, Esq., Stephen R. Smerek, Esq. (argued), Jason C. Hamilton, Esq., WINSTON & STRAWN, LLP, Los Angeles, CA; Melinda K. Lackey, Esq., Donald H. Mahoney, III, Esq., WINSTON & STRAWN LLP, Houston, TX.

Attorneys for Defendant Watson Laboratories, Inc.

John W. Shaw, Esq., Karen E. Keller, Esq., David M. Fry, Esq., SHAW KELLER LLP, Wilmington, DE; Elaine Blais, Esq. (argued), Robert Frederickson, III, Esq. (argued), Alexandra Lu, Esq., Kathryn Kosinski, Esq., GOODWIN PROCTER LLP, Boston, MA; Robert V. Cerwinski, Esq. (argued), GOODWIN PROCTER LLP, New York, NY; John Coy Stull, Esq., GOODWIN PROCTER LLP, Washington, D.C.

Attorneys for Defendant Teva Pharmaceuticals USA, Inc.

Steven J. Fineman, Esq., Katharine Lester Mowery, Esq., RICHARDS LAYTON & FINGER, P.A., Wilmington, DE; Jennifer Koh, Esq., B. Thomas Watson, Esq., LATHAM & WATKINS LLP, San Diego, CA; Emily C. Melvin, Esq., Brenda L. Danek, Esq., LATHAM & WATKINS LLP, Chicago, IL; Terrance Kearney, Esq., Michelle P. Woodhouse, Esq., LATHAM & WATKINS LLP, Menlo Park, CA.

Attorneys for Defendants Par Pharmaceutical, Inc. and Intelgenx Technologies Corp.

June 29, 2016

  
ANDREWS, U.S. DISTRICT JUDGE:

Presently before the Court is the issue of claim construction of multiple terms in U.S. Patent Nos. 8,906,277 (“the ’277 patent”), 8,900,497 (“the ’497 patent”), 8,603,514 (“the ’514 patent”), 8,475,832 (“the ’832 patent”), and 8,017,150 (“the ’150 patent”). The Court has considered the Parties’ Joint Claim Construction Brief. (D.I. 108).<sup>1</sup> The Court heard oral argument on March 31, 2016. (D.I. 174).

## I. BACKGROUND

The present claim construction dispute arises from Hatch-Waxman litigation involving Suboxone® sublingual film, Plaintiffs’ pharmaceutical film product for the treatment of opioid dependence. The parties divide the five patents at issue into two groupings: the process patents and the Orange Book patents. The process patents, which include the ’277 and ’497 patents, claim processes for manufacturing pharmaceutical films. The process patents are asserted against the Defendants in all three of the present actions.

The Orange Book patents, which include the ’150, ’832, and ’514 patents, claim various pharmaceutical film compositions. Plaintiffs’ actions for infringement of the Orange Book patents against Defendants Watson and Par have already gone to trial and I have issued a final decision on the merits. (C.A. No. 13-1674-RGA, D.I. 446). Accordingly, the proposed claim constructions offered here for the ’514, ’832, and ’150 patents only involve Civil Action No. 14-1451-RGA, Plaintiffs’ action against Defendant Teva.

## II. LEGAL STANDARD

“It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” *Phillips v. AWH Corp.*, 415 F.3d 1303, 1312

---

<sup>1</sup> Unless otherwise specifically noted, all references to the docket refer to Civil Action No. 14-1451-RGA.

(Fed. Cir. 2005) (en banc) (internal quotation marks omitted). “[T]here is no magic formula or catechism for conducting claim construction.’ Instead, the court is free to attach the appropriate weight to appropriate sources ‘in light of the statutes and policies that inform patent law.’”

*SoftView LLC v. Apple Inc.*, 2013 WL 4758195, at \*1 (D. Del. Sept. 4, 2013) (quoting *Phillips*, 415 F.3d at 1324) (alteration in original). When construing patent claims, a court considers the literal language of the claim, the patent specification, and the prosecution history. *Markman v. Westview Instruments, Inc.*, 52 F.3d 967, 977–80 (Fed. Cir. 1995) (en banc), *aff’d*, 517 U.S. 370 (1996). Of these sources, “the specification is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.” *Phillips*, 415 F.3d at 1315 (internal quotation marks omitted).

“[T]he words of a claim are generally given their ordinary and customary meaning. . . . [Which is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” *Id.* at 1312–13 (citations and internal quotation marks omitted). “[T]he ordinary meaning of a claim term is its meaning to [an] ordinary artisan after reading the entire patent.” *Id.* at 1321 (internal quotation marks omitted). “In some cases, the ordinary meaning of claim language as understood by a person of skill in the art may be readily apparent even to lay judges, and claim construction in such cases involves little more than the application of the widely accepted meaning of commonly understood words.” *Id.* at 1314.

When a court relies solely upon the intrinsic evidence—the patent claims, the specification, and the prosecution history—the court’s construction is a determination of law. *See Teva Pharm. USA, Inc. v. Sandoz, Inc.*, 135 S. Ct. 831, 841 (2015). The court may also make factual findings based upon consideration of extrinsic evidence, which “consists of all

evidence external to the patent and prosecution history, including expert and inventor testimony, dictionaries, and learned treatises.” *Phillips*, 415 F.3d at 1317–19 (internal quotation marks omitted). Extrinsic evidence may assist the court in understanding the underlying technology, the meaning of terms to one skilled in the art, and how the invention works. *Id.* Extrinsic evidence, however, is less reliable and less useful in claim construction than the patent and its prosecution history. *Id.*

“A claim construction is persuasive, not because it follows a certain rule, but because it defines terms in the context of the whole patent.” *Renishaw PLC v. Marposs Societa’ per Azioni*, 158 F.3d 1243, 1250 (Fed. Cir. 1998). It follows that “a claim interpretation that would exclude the inventor’s device is rarely the correct interpretation.” *Osram GMBH v. Int’l Trade Comm’n*, 505 F.3d 1351, 1358 (Fed. Cir. 2007) (citation and internal quotation marks omitted).

### III. CONSTRUCTION OF DISPUTED TERMS

#### A. The ’277 and ’497 Patents (the Process Patents)

The ’277 and ’497 patents both claim processes for making pharmaceutical films that contain substantially uniform amounts of the active ingredient. The two patents contain nearly identical specifications. Claim 1 of the ’497 patent is representative and reads as follows:

1. A process for making a film having a substantially uniform distribution of components, comprising the steps of:
  - (a) forming a flowable polymer matrix comprising an edible polymer, a solvent and a desired amount of at least one active, said matrix having a substantially uniform distribution of said at least one active;
  - (b) casting said flowable polymer matrix;
  - (c) rapidly evaporating at least a portion of said solvent upon initiation of drying to form a visco-elastic film within about the first 4.0 minutes to maintain said substantially uniform distribution of said at least one active by locking-in or substantially preventing migration of said at least one active within said visco-elastic film;

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.